The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
PhaseBio Pharmaceuticals, Inc(NASDAQ:PHAS)


PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical ...
Website: http://www.phasebio.com
Founded: 2002
Full Time Employees: 50 (May 2021)
Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals Op Cashflow Per Share ttm
PhaseBio Pharmaceuticals Free Cashflow Per Share ttm
PhaseBio Pharmaceuticals Cash Per Share ttm
PhaseBio Pharmaceuticals P/S ratio ttm
PhaseBio Pharmaceuticals (GAAP) P/E ratio ttm
PhaseBio Pharmaceuticals P/B ratio ttm
No extra charts and metrics for this ticker.